The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Articles|August 1, 2009
- Applied Clinical Trials-08-01-2009
- Volume 0
- Issue 0
Applied Clinical Trials Digital Edition - August 2009
EDC : Getting it Right - EDC Rescue Studies INFORMATION TECHNOLOGY : How Health Intelligence Leads to Smarter Research CRO/SPONSOR : The Proactive Advantage in Risk Management Also in this issue : All Eyes on R&D as U.S. Talks Health Care, Fragmented System Stifling EU Research, IT Convergence: Are We There Yet?, Why Virtual Meetings Make Sense
Advertisement
Articles in this issue
about 17 years ago
eClinical Software: August 2009about 17 years ago
Welcome to the Age of Convergenceabout 17 years ago
Health Reform Shapes Drug Developmentabout 17 years ago
From EDC Emerges eClinicalabout 17 years ago
WHO Boosts Research in Africaabout 17 years ago
Disharmony Stifling Research in Europeabout 17 years ago
A Market Worth Watchingabout 17 years ago
By Land, Air or Better Yet...PCabout 17 years ago
Reducing Risk Through Mitigation Strategiesabout 17 years ago
Information as a Strategic AssetAdvertisement
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
5